dc.contributor.author | Larsen, Christopher Storm | |
dc.contributor.author | Myhr, Kjell-Morten | |
dc.contributor.author | Farbu, Elisabeth | |
dc.contributor.author | Midgard, Rune | |
dc.contributor.author | Nyquist, Kaja Beate | |
dc.contributor.author | Broch, Line | |
dc.contributor.author | Berg-Hansen, Pål | |
dc.contributor.author | Buness, A. | |
dc.contributor.author | Holm, Kristian | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Fallang, Lars-Egil | |
dc.contributor.author | Burum-Auensen, Espen | |
dc.contributor.author | Hov, Johannes Espolin Roksund | |
dc.contributor.author | Holmøy, Trygve | |
dc.date.accessioned | 2020-06-04T14:06:02Z | |
dc.date.available | 2020-06-04T14:06:02Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Mult Scler J Exp Transl Clin . 2019 Nov 15;5(4). eCollection Oct-Dec 2019. | en_US |
dc.identifier.issn | 2055-2173 | |
dc.identifier.uri | https://hdl.handle.net/11250/2656624 | |
dc.description.abstract | Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associated with gastrointestinal side-effects in some patients.
Objectives: The purpose of this study was to determine if dimethyl fumarate alters the abundance and diversity of commensal gut bacteria, and if these changes are associated with gastrointestinal side-effects.
Methods: Thirty-six patients with relapsing-remitting multiple sclerosis received either dimethyl fumarate (n = 27) or an injectable multiple sclerosis disease-modifying therapy (glatiramer acetate or interferons, n = 9) for 12 weeks. Stool samples were collected at baseline, two and 12 weeks. We included 165 healthy individuals as controls.
Results: At baseline, 16 microbial genera were altered in multiple sclerosis patients compared with healthy controls. In the dimethyl fumarate-treated patients (n = 21) we observed a trend of reduced Actinobacteria (p = 0.03, QFDR = 0.24) at two weeks, mainly driven by Bifidobacterium (p = 0.06, QFDR = 0.69). At 12 weeks, we observed an increased abundance of Firmicutes (p = 0.02, QFDR = 0.09), mostly driven by Faecalibacterium (p = 0.01, QFDR = 0.48).
Conclusions: This pilot study did not detect a major effect of dimethyl fumarate on the gut microbiota composition, but we observed a trend towards normalization of the low abundance of butyrate-producing Faecalibacterium after 12 weeks treatment. The study was underpowered to link microbiota to gastrointestinal symptoms. | en_US |
dc.description.sponsorship | The author(s) disclosed receipt of the following financialsupport for the research, authorship, and/or publicationofthis article: This work was supported by Biogen. This clinical trial is registered at clinicaltrials.gov (identifier NCT02471560). | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.subject | Gastrointestinal microbiome; | en_US |
dc.subject | clinical trial; | en_US |
dc.subject | dimethyl fumarate; | en_US |
dc.subject | faecalibacterium; | en_US |
dc.subject | gastrointestinal symptoms; | en_US |
dc.subject | multiple sclerosis | en_US |
dc.title | Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © The Author(s) 2019.
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution ofthe workwithout further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). | en_US |
dc.source.pagenumber | 1-13 | en_US |
dc.source.volume | 5 | en_US |
dc.source.journal | Multiple Sclerosis Journal, Experimental, Translational and Clinical | en_US |
dc.source.issue | 4 | en_US |
dc.identifier.doi | 10.1177/2055217319888767 | |
dc.identifier.cristin | 1790210 | |